Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 8,587 Shares of Stock

Posted by Brenda Bartman on Jun 19th, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) COO Kristen Oelschlager sold 8,587 shares of Castle Biosciences stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $20.71, for a total transaction of $177,836.77. Following the completion of the sale, the chief operating officer directly owned 30,460 shares in the company, valued at $630,826.60. This represents a 21.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL opened at $21.12 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.53 and a current ratio of 6.75. The firm has a fifty day moving average of $21.82 and a 200 day moving average of $29.77. The firm has a market cap of $640.57 million, a PE ratio of -48.00 and a beta of 1.04. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.49). The business had revenue of $84.23 million for the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. As a group, research analysts predict that Castle Biosciences, Inc. will post -1.4 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on CSTL. Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. Robert W. Baird lowered their price target on Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Canaccord Genuity Group lowered their price target on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. BTIG Research reduced their price objective on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, Wall Street Zen downgraded Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

Check Out Our Latest Report on Castle Biosciences

Institutional Trading of Castle Biosciences

Several large investors have recently bought and sold shares of the business. Federated Hermes Inc. purchased a new position in Castle Biosciences in the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Castle Biosciences in the fourth quarter valued at approximately $35,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Castle Biosciences by 140.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock worth $68,000 after buying an additional 1,022 shares in the last quarter. Finally, CWM LLC boosted its stake in Castle Biosciences by 20.5% during the fourth quarter. CWM LLC now owns 2,302 shares of the company’s stock worth $90,000 after buying an additional 391 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.